

## **Medigenomix Acquires an Exclusive License for the use of Genetic Polymorphisms in G-Proteins for Applications in Pharmacogenetics**

**Brussels/ Munich, September 18, 2003**

Medigenomix, a subsidiary of the Eurofins Group based in Munich/ Germany, recently signed an exclusive license agreement with SNiP Biotech GmbH & Co KG, Essen, for patented SNPs (Single Nucleotide Polymorphisms) in the gene GNB3 coding for a G-protein subunit. As G-proteins play a central role in the signal transduction of all human cells, these SNPs can be used for multiple applications, both in pharmacogenetics and in predictive medicine.

Moreover, a contract for consultancy was signed with Prof. Dr. Winfried Siffert, Department of Pharmacology at the University of Duisburg-Essen Medical School. Prof. Dr. Winfried Siffert is one of the leading experts with long-term experience in the detection and validation of polymorphisms in genes encoding G-proteins. His support will provide the Medigenomix customers with professional advice and assures that they can benefit from additional proprietary SNPs that are currently in the final validation steps.

With these strategic steps, Medigenomix completes its portfolio of SNP analyses and strengthens its expertise in the field of pharmacogenetics. The company is now able to offer valuable exclusive services with validated genetic markers to the biopharmaceutical industry for improving drug development and accelerating phase I-IV clinical trials.

### **Direct access to transduction processes by testing on SNPs coding for G-proteins**

The central aim of pharmacogenetics is the prediction of responders/ non-responders to certain drugs and the identification of individuals at risk for adverse drug reactions based on the knowledge on variations in relevant genes. Many laboratories are specialised on identifying variations in genes coding for drug-metabolising enzymes, drug-transporters or receptors.

SNiP-Biotech, however, focuses on genes, which code for G-proteins, as they are pivotal for signal transduction processes from receptors to intracellular components. Based on this approach, SNiP-Biotech identified patterns of genes and genetic polymorphisms, which allow to predict at a new level of precision not only drug effects, but also risks for diseases and the natural course of common disorders. The associated gene tests have been validated in clinical trials and are subject to issued patents and pending patent applications.

### **Broad spectrum of applications in the pharmaceutical industry**

Medigenomix offers these new, validated methods to the biopharmaceutical industry on a commercial basis with scientific support of Prof. Siffert. Examples for commercial applications in the biopharmaceutical industry are:

- Identification of responders/ non responders in phase I-IV clinical trials;
- Identification of individuals at risk for adverse drug reactions;
- Recruitment of responders for phase II- IV clinical trials;
- Individualised dosage adjustment;

- Re-evaluation of failed clinical studies or drugs based on pharmacogenetic aspects.

Medigenomix' offer does not only include high-quality DNA genotyping, but also scientific consultation in the planning phase, during the set-up and when establishing pharmacogenetic methods in clinical trials. In addition, the company is able to give expert advice on evaluation and interpretation of results. Medigenomix supports customers in detecting underlying mechanism of drug efficacy and offers the exclusive use of the genetic tests for defined indications on the basis of license agreements. Further applications lay in the field of predictive genetic diagnostics.

Medigenomix is a well-established service provider of DNA analysis with long standing expertise in genotyping for a variety of applications. The gene tests will also be part of the portfolio for clinical trials, which Medigenomix offers jointly with Analytico.Medinet, its partner in the Eurofins-Group. Analytico.Medinet, one of the leading pharmaceutical laboratories in Europe, provides global standardised laboratory service within clinical trials, which will be further strengthened by the integration of Medigenomix' new proprietary G-protein polymorphisms assays.

**For further information please visit [www.medigenomix.com](http://www.medigenomix.com) or contact:**

- **Technical & commercial inquiries**

Dr. Brigitte Obermaier  
Dr. Engelbert Precht  
(Managing Directors, Medigenomix)  
Phone: +49-89-89 98 92-0  
Email: [precht@medigenomix.de](mailto:precht@medigenomix.de)

- **Investor Relations**

Dr. Stefan Eckhoff  
(International Investor Relations)  
Phone: +32-2-766 16 20  
E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

Hugues Vaussy  
(Investor Relations France)  
Phone: +33-2-51 83 21 00  
E-mail: [irFrance@eurofins.com](mailto:irFrance@eurofins.com)

**Notes for the editor:**

Eurofins Scientific is a biotechnology company operating internationally to provide a comprehensive range of bioanalytical support services. The Group specialises in delivering analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. The Eurofins Group aims to become a world market leader in this field of applied life sciences and is pursuing a dynamic expansion strategy to add to both, its technology portfolio and its geographic reach.

With over 2,000 staff in more than 50 laboratories across 12 countries and a portfolio of around 5,000 reliable analytical methods for proving the authenticity, origin, safety, identity, and purity of biological substances, Eurofins Scientific is already a leading global provider of bioanalytical services. The Group is committed to supporting its clients' objective of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate. Eurofins Scientific intends to continue to develop, acquire or license the most comprehensive range of state-of-the-art analytical technologies in order to support its clients' increasingly stringent quality and safety standards and the demands of regulatory bodies around the World.

The shares of Eurofins Scientific are listed on Euronext in Paris and on the Stock Exchange in Frankfurt and traded through Euronext from Amsterdam, Brussels and Lisbon.

**Important disclaimer:**

This press release might contain forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements.